Thursday, July 26, 2007
Carolyn Benivegna and Sandi Pniauskas
contact: Sandi Pniauskas 905 668-0767
further information/registration: http://ovariancancerdebate.blogspot.com
online poll: http://cancerissues.blogspot.com/
Survivors' Debate: “The Past Decade in Ovarian Cancer”
WHAT: Ovarian cancer survivors, Carolyn Benivegna (U.S.) and Sandi Pniauskas (Canada), announce the first ever Ovarian Cancer Survivors Debate. The two conferences are survivor-led and survivor-organized with debate and discussion surrounding the multitude of issues - the past and the present. Open and lively dialogue will be encouraged.
WHO SHOULD ATTEND: All cancer survivors/caregivers, healthcare professionals, researchers, pharmacists and the general public are encouraged to attend and participate.
#1: Sheraton Hotel, Novi, MI Sat. October 27th, 2007
#2: Metropolitan Hotel, Toronto, ON Sat. November 3rd, 2007
Time: 10:00 am - 12:30 pm
Ovarian cancer has the highest mortality rate of all gynecologic cancers. Ovarian cancer has no early detection test. The debate and ensuing open forum public discussions will include the specifics of disease-related issues including genetics, access to care and communications. Carolyn Benivegna is a nine year ovarian cancer survivor, a BRCA1 carrier and Founder/Board Member of OCAG-GC. Sandi Pniauskas is an eight ovarian cancer survivor with a genetic predisposition to Lynch Syndrome/Hereditary NonPolyposis Colorectal Cancer and a member of the Cochrane Collaboration. Carolyn and Sandi are energetic, knowledgeable ovarian cancer advocates and activists since the beginning of their journeys.
Ovarian cancer survivors Annamarie DeCarlo and Dr. Yi Pan will co-moderate both events. Bridget Capo (R.N.) and Pamela J. West (R.N.) will provide support and collaborate with Benivegna and Pniauskas in formal publication of the event proceedings.
Friday, July 20, 2007
Sunday, July 15, 2007
Sandi's comments: One of the issues that I have is the reference in the article: "If you're a woman with Lynch syndrome, you may want to mention this study to your doctor and get her take on how it might apply to you."
As a generalization, the vast majority of hcps have never heard of the Lynch Syndrome (HNPCC).
Lynch Syndrome - Cancer Prevention with Lynch Syndrome: "If you're a woman with Lynch syndrome, you may want to mention this study to your doctor and get her take on how it might apply to you."
Saturday, July 14, 2007
The quality of the operative report for women with...[J Obstet Gynaecol Can. 2006] - PubMed Result: "
[Click to change filter selection through My NCBI.]
1: J Obstet Gynaecol Can. 2006 Oct;28(10):892-7."
J Obstet Gynaecol Can. 2006 Oct;28(10):892-7.
The quality of the operative report for women with ovarian cancer in Ontario.
Elit L, Bondy S, Chen Z, Law C, Paszat L.
Department of Obstetrics and Gynecology, McMaster University, Hamilton, ON, Canada.
OBJECTIVE: To assess the quality of the operative reports from cases of ovarian cancer surgery in Ontario.
METHODS: We undertook a population cohort study including all newly diagnosed ovarian cancer patients treated initially with surgery from January 1996 to December 1998 in Ontario (n = 1341). We abstracted charts from hospitals and cancer centres. All surgical and pathology notes were abstracted into an ACCESS database.
RESULTS: A total of 1,341 women had surgery as the first step in management of ovarian cancer. A vertical abdominal incision was used in 87.6% of these cases. Peritoneal cytology was obtained in 87.8% of cases overall, but in only 69.5% of stage 1 cases. A description of the ovaries was provided in 85% of reports, of the uterus in 70%, the diaphragm in 53%, the liver in 69%, the pelvic lymph nodes in 10%, and the para-aortic lymph nodes in 41%. In stage 1 cases, the ovaries were assessed histologically in 89% of cases, the uterus in 80%, the omentum in 69%, the peritoneum in 20%, the appendix in 9%, the pelvic lymph nodes in 10%, and the para-aortic lymph nodes in 7%. Frozen section was obtained in half of the stage 1 cases, and the false negative rate for identifying malignancy was 6%. In all, 23% of women received adequate surgical staging for stage 1 disease, and 12% of women with advanced disease had optimal debulking (to less than 1 cm residual disease). There are clear differences between centres with a gynaecologic oncologist on staff and other centres in the adequacy of surgical staging in women with stage 1 disease (chi2 = 60.6, P < 0.0001) and in optimal debulking for advanced disease (chi2 = 39.1, P < 0.0001). In 40% of cases with advanced disease, the amount of residual disease following surgery is not reported.
CONCLUSION: The current approach of dictating operative notes does not provide sufficient detail in a large number of cases; this affects treatment decisions and limits our ability to assess quality indicators for operative care in ovarian cancer. This problem is pervasive but is more significant in centres without a gynaecologic oncologist.